moatshark My

All holdings

Kodiak Sciences

KOD

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$1.4m
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q2 ’26 end
$38.96
+2.2% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+70.8%Q4 ’25
+36.3%Q1 ’26
+2.2%Q2 ’26
Q4 ’25: +70.8%; Q1 ’26: +36.3%; Q2 ’26: +2.2%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
0Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 0; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Kodiak Sciences.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Kodiak Sciences
Polen Capital Management0.0%$1.4m$1.4mTrimmed -14%4 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Kodiak Sciences
Bought or soldFiling
29 Sep 2026Baker Bros. Advisors LPDirector▲ Bought20,031$85.40$1.7mForm 4
29 Sep 2026Baker Bros. Advisors LPDirector▲ Bought10,381$84.24$875kForm 4
29 Sep 2026Baker Bros. Advisors LPDirector▲ Bought1,416$85.89$122kForm 4
29 Sep 2026Baker Bros. Advisors LPDirector▲ Bought1,195$85.40$102kForm 4
29 Sep 2026Baker Bros. Advisors LPDirector▲ Bought619$84.24$52kForm 4
29 Sep 2026Baker Bros. Advisors LPDirector▲ Bought84$85.89$7kForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought278,978$72.39$20.2mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought196,608$89.86$17.7mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought123,888$83.95$10.4mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought107,772$88.65$9.6mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought109,842$84.85$9.3mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought98,561$88.57$8.7mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought82,673$89.60$7.4mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought75,176$87.51$6.6mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought78,726$73.08$5.8mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought76,723$73.97$5.7mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought63,539$86.94$5.5mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought61,700$76.34$4.7mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought49,771$78.57$3.9mForm 4
28 Sep 2026Baker Bros. Advisors LPDirector▲ Bought48,350$77.43$3.7mForm 4

About the company

Sector
Health care · Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
63m at 6 Aug 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

Kodiak Sciences revenue and net income by year
YearRevenueNet income
2025–−$230m
2024–−$176m
2023–−$260m
2022–−$334m
2021–−$267m
2020–−$133m
2019–−$47.4m
2018–−$41.4m
2017–−$27.9m
2016–−$17.1m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.